Syed Subhani1, Kaiser Jamil2, Sharanabasappa Somanath Nirni3. 1. Genetics Department, Bhagwan Mahavir Medical Research Centre, #10-1-1, Mahavir Marg, Masab Tank, Hyderabad, 500004, Telangana, India. 2. Genetics Department, Bhagwan Mahavir Medical Research Centre, #10-1-1, Mahavir Marg, Masab Tank, Hyderabad, 500004, Telangana, India. kaiser.jamil@gmail.com. 3. Omega Hospitals, Banjara Hills, Hyderabad, Telangana, India.
Abstract
INTRODUCTION: Chemotherapy is the standard and recommended treatment for lung cancer apart from surgery and radiotherapy. Chemotherapy is administered as mono-agents or as combination therapy. In this study, we examined the role of MDR1 C3435T polymorphisms in lung cancer patients undergoing chemotherapy. METHODS AND RESULTS: We genotyped 126 cases with lung cancer and 111 healthy controls, using the polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). Frequencies of MDR1 C3435C, C3435T and T3435T genotypes were 61, 16 and 23 % in lung cancer patients and 86, 9 and 5 % in the controls, respectively. The T3435T genotypes had a 5.23-fold increased risk for lung cancer. (OR 5.23; 95 % CI 2.082-13.146; p = 0.0004). Patients with TT genotypes were more frequent in stage IV and were significantly associated with the disease (p = 0.05). Habitual smoker lung cancer patients were 50 % CC genotypes whereas TT genotypes were 34 %. The non-smokers had 46 % CC genotypes and 23 % TT genotypes. Furthermore, we collected tissue biopsy samples for expression analysis from 20 patients (for controls we used the non-cancerous region of the same tissue). The present study showed mRNA expression of MDR1 was up-regulated in 80 % of the cancer group in comparison with the control group (p = 0.0002). We also correlated the association between MDR1 genotypes with different combinations of chemotherapy. The combinations and genotype distributions in the group receiving paclitaxel + cisplatin were as follows: CC (67 %), CT (24 %) and TT (9 %) genotypes, respectively, and the group receiving carboplatin + gemcitabine CC (46 %), CT (19 %) and TT (35 %) genotypes, respectively. We found that MDR1 (rs1045642) C3435T polymorphism and gene expression was significantly associated with the clinical outcome in lung carcinoma patients. CONCLUSION: In conclusion, it is suggested that MDR1 TT genotypes had higher risk for the development of lung cancer. Also, this polymorphism could be used as a genetic marker for predicting the clinical outcome of lung cancer patients.
INTRODUCTION: Chemotherapy is the standard and recommended treatment for lung cancer apart from surgery and radiotherapy. Chemotherapy is administered as mono-agents or as combination therapy. In this study, we examined the role of MDR1C3435T polymorphisms in lung cancerpatients undergoing chemotherapy. METHODS AND RESULTS: We genotyped 126 cases with lung cancer and 111 healthy controls, using the polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). Frequencies of MDR1 C3435C, C3435T and T3435T genotypes were 61, 16 and 23 % in lung cancerpatients and 86, 9 and 5 % in the controls, respectively. The T3435T genotypes had a 5.23-fold increased risk for lung cancer. (OR 5.23; 95 % CI 2.082-13.146; p = 0.0004). Patients with TT genotypes were more frequent in stage IV and were significantly associated with the disease (p = 0.05). Habitual smoker lung cancerpatients were 50 % CC genotypes whereas TT genotypes were 34 %. The non-smokers had 46 % CC genotypes and 23 % TT genotypes. Furthermore, we collected tissue biopsy samples for expression analysis from 20 patients (for controls we used the non-cancerous region of the same tissue). The present study showed mRNA expression of MDR1 was up-regulated in 80 % of the cancer group in comparison with the control group (p = 0.0002). We also correlated the association between MDR1 genotypes with different combinations of chemotherapy. The combinations and genotype distributions in the group receiving paclitaxel + cisplatin were as follows: CC (67 %), CT (24 %) and TT (9 %) genotypes, respectively, and the group receiving carboplatin + gemcitabine CC (46 %), CT (19 %) and TT (35 %) genotypes, respectively. We found that MDR1 (rs1045642) C3435T polymorphism and gene expression was significantly associated with the clinical outcome in lung carcinomapatients. CONCLUSION: In conclusion, it is suggested that MDR1 TT genotypes had higher risk for the development of lung cancer. Also, this polymorphism could be used as a genetic marker for predicting the clinical outcome of lung cancerpatients.
Authors: I Cascorbi; T Gerloff; A Johne; C Meisel; S Hoffmeyer; M Schwab; E Schaeffeler; M Eichelbaum; U Brinkmann; I Roots Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875
Authors: Thomas Illmer; Ulrich S Schuler; Christian Thiede; Ute I Schwarz; Richard B Kim; Sebastian Gotthard; Daniel Freund; Ulrike Schäkel; Gerhard Ehninger; Markus Schaich Journal: Cancer Res Date: 2002-09-01 Impact factor: 12.701
Authors: Irma Olarte Carrillo; Anel Irais García Laguna; Adrián De la Cruz Rosas; Christian Omar Ramos Peñafiel; Juan Collazo Jaloma; Adolfo Martínez Tovar Journal: BMC Med Genomics Date: 2021-10-26 Impact factor: 3.063